Abstract: Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.
Type:
Grant
Filed:
November 15, 2022
Date of Patent:
March 12, 2024
Assignee:
Cancer Prevention Pharmaceuticals, Inc.
Inventors:
Patrick Shannon, Roberto Carlos Bravo González, Jean Ducassou
Abstract: Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.
Type:
Application
Filed:
November 15, 2022
Publication date:
June 8, 2023
Applicant:
Cancer Prevention Pharmaceuticals, Inc.
Inventors:
Patrick SHANNON, Roberto Carlos BRAVO GONZÁLEZ, Jean DUCASSOU
Abstract: Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.
Type:
Grant
Filed:
March 5, 2021
Date of Patent:
December 20, 2022
Assignee:
Cancer Prevention Pharmaceuticals, Inc.
Inventors:
Patrick Shannon, Roberto Carlos Bravo González, Jean Ducassou
Abstract: Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.
Type:
Grant
Filed:
October 31, 2016
Date of Patent:
April 13, 2021
Assignee:
CANCER PREVENTION PHARMACEUTICALS, INC.
Inventors:
Patrick Shannon, Roberto Carlos Bravo González, Jean Ducassou
Abstract: Provided are methods for preventing or delaying the need for surgical intervention in a patient having familial adenomatous polyposis (FAP) and an at least partially intact lower gastrointestinal tract. Also provided are methods for preventing or delaying the formation of neoplasia and/or cancer in a patient having FAP. The methods comprise administering an effective amount of a pharmaceutical therapy that comprises eflornithine and sulindac to a patient having FAP and an intact lower gastrointestinal tract.
Type:
Grant
Filed:
May 15, 2020
Date of Patent:
March 16, 2021
Assignee:
Cancer Prevention Pharmaceuticals, Inc.
Inventors:
Eugene Gerner, Alfred Cohen, Michelle Boytim
Abstract: Controlling exogenous polyamines may be used, in some aspects, as an adjunctive strategy to chemoprevention with polyamine inhibitory agents, for example, anti-carcinoma combination therapies comprising ornithine decarboxylase (ODC) inhibitor and a spermidine/spermine N1-acetyltransferase expression agonist, optionally based on a patient's ODC1 promoter genotype. Assessing a tissue polyamine level or tissue polyamine flux may be used in some aspects, for predicting the efficacy of an anti-carcinoma combination therapy comprising, for example, an ornithine decarboxylase (ODC) inhibitor and an agent that modulates the polyamine pathway to reduce overall cellular polyamine content.
Type:
Application
Filed:
May 13, 2011
Publication date:
August 22, 2013
Applicants:
CANCER PREVENTION PHARMACEUTICALS, INC., CANCER PREVENTION PHARMACEUTICAL, INC, THE REGENT OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION
Inventors:
Kavitha P. Raj, Jason A. Zell, Christine E. Mclaren, Eugene W. Gerner, Frank L. Meyskens, JR., Jeffrey Jacob